海外の治験の状況「1」での検索結果
11979件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not recruiting
- Inactive FSH in Galactosemia
- Galactosemia;Premature Ovarian Failure
- Netherlands
- 2008-02-06
Authorised
- ENSAYO PILOTO CON IMATINIB PARA PACIENTES CON NEUROFIBROMA PLEXIFORME ASOCIADO A LA NEUROFIBROMATOSIS TIPO I. PILOT STUDY WITH IMATINIB FOR PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE I PATIENTS
- Tratamiento de los neurofibromas plexiformes de alto riesgo no abordables quirúrgicamente en pacientes con neurofibromatosis tipo I
- Spain
- 2009-11-19
Not Recruiting
- The effect of long-term simvastatin treatment on cognitive function and daily life in children with Neurofibromatosis 1: a one year randomized controlled trial
- Neurofibromatosis 1
- Netherlands
- 2009-09-21
Not recruiting
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen
- HIV Infections;HIV Infections;HIV Infections;HIV Infections
- Argentina, Australia, Chile, China, France, Germany, Hong Kong, India, Ireland, Malaysia, Mexico, New Zealand, Nigeria, Peru, Singapore, South Africa, Taiwan, United Kingdom, Vietnam
- 2009-07-01
Authorised
- [Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus] Target-specific therapy of metastatic urothelial carcinoma with temsirolimus - Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus
- Chemotherapy refractory metastatic urothelia carcinoma MedDRA version: 9.1 Level: LLT Classification code 10064467 Term: Urothelial carcinoma
- Germany
- 2009-01-20
Not Recruiting
- Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus - ND
- prevention of type 1 diabetes mellitus in subjects at risk for T1DM MedDRA version: 9.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus
- Finland, Germany, Italy, Sweden, United Kingdom
- 2008-04-23
Not Recruiting
- Evaluation of [11C]-methionine positron emission computerised tomography (PET CT) in diagnosing neurofibromatosis 1(NF1) - malignant peripheral nerve sheath tumours (MPNST) - Methionine PET
- The diagnosis of malignant peripheral nerve sheath tumours in patients with neurofibromatosis 1 br>MedDRA version: 12 Level: LLT Classification code 10029268 Term: Neurofibromatosis 1 associated malignant peripheral nerve sheath tumour
- United Kingdom
- 2010-12-13
Not recruiting
- Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
- Facial Rhytides;Crow's Feet Lines;Glabellar Lines;Facial Rhytides;Crow's Feet Lines;Glabellar Lines;Facial Rhytides;Crow's Feet Lines;Glabellar Lines;Facial Rhytides;Crow's Feet Lines;Glabellar Lines
- Canada, France, Germany, United States
- 2010-10-18
Not Recruiting
- A phase I/IIa sporozoite challenge study to assess the safety, immunogenicity and protective efficacy of new malaria vaccine candidates; AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP. - Blood & Liver Stage Viral Vectored Vaccines Challenge Study
- Malaria (plasmodium falciparum)
- United Kingdom
- 2010-03-18
Not Recruiting
- A mono-center, open label, randomised 2-period crossover study to compare the pharmacokinetics and pharmacodynamics of continuous insulin infusion administered either intradermally or subcutaneously in subjects with type 1 diabetes mellitus
- Type 1 diabetes mellitus br>MedDRA version: 12.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus
- Germany
- 2009-11-09
Authorised
- AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB - BEBYP
- METASTATIC COLORECTAL CANCER PATIENTS MedDRA version: 9.1 Level: LLT Classification code 10052358 Term: Colorectal cancer metastatic
- Italy
- 2008-02-06
Authorised
- Use of biological marker (ABCB1/P-glycoprotein) as factor able to distinguish patients having different risk of recurrence in osteosarcoma
- Non metastatic osteosarcoma of the extremities MedDRA version: 14.0 Level: PT Classification code 10031293 Term: Osteosarcoma localised System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2011-09-02
Not Recruiting
- A phase IIa, double-blinded, randomized trial comparing the efficacy and safety of BioChaperone® rhInsulin to fast-acting insulin analog in patients with Type 1 Diabetes mellitus
- Diabetes mellitus MedDRA version: 13.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders MedDRA version: 13.1 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Germany
- 2011-03-30
Recruiting
- A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two
- Diabetes;E10 - Insulin-dependent diabetes mellitus
- Argentina, Belarus, Belgium, Canada, Chile, Germany, Japan, Netherlands, Poland, Russian Federation, Sweden, Switzerland, United Kingdom, United States
- 2016-01-28
Not Recruiting
- A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma - -
- Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma MedDRA version 6.0 PT=Hodgkin's Disease NOS recurrent=10020256 PT=Hodgkin's Disease NOS refractory=10020257 PT=Anaplastic large cell lymphoma T- and null-cell types recurrent=1002229 PT=Anaplastic large cell lymphoma T- and null-cell types refractory=1002230 MedDRA version: 6.0 Level: PT Classification code 10020256
- Denmark, Italy, Sweden
- 2004-08-04
Authorised
- Comparison between beta-adrenergic blockers and angiotensin II receptor antagonists for the treatment of late hypertension in patients with repaired aortic coarctation - Treatment of late hypertension in aortic coarctation
- Aortic coarctation and late hypertension
- Netherlands
- 2006-12-22
Not Recruiting
- A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS.
- Type 1 Diabetes MedDRA version: 8.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus
- Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Netherlands, Portugal, Sweden, United Kingdom
- 2006-10-26
Not recruiting
- Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
- Renal Cell Carcinoma;Renal Cell Carcinoma;Renal Cell Carcinoma;Renal Cell Carcinoma
- Argentina, Australia, Austria, Canada, Chile, China, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, United Kingdom, United States
- 2007-05-15
Not Recruiting
- A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy
- Patients with relapsed multiple myeloma who have received at least two prior lines of therapy and whose disease is refractory to the most recent line of therapy. Prior therapy must have included bortezomib or lenalidomide. MedDRA version: 8.1 Level: LLT Classification code 10028228 Term: Multiple myeloma
- France, Germany, Italy, Netherlands
- 2007-01-26
Not Recruiting
- A Pivotal Long-Term, Open-Label, Parallel Study of the Efficacy and Safety of Human Insulin Inhalation Powder in Patients with Type 1 Diabetes Mellitus - IDAH
- Patients with type 1 diabetes mellitus and many patients with type 2 diabetes mellitus require daily use of insulin for the maintenance of normal glucose homeostasis. At present, insulin can be delivered only by injection. The availability of noninjectable routes of insulin administration may eliminate a barrier to effective therapy and improve the quality of life for many patients with diabetes.
- Hungary
- 2005-11-22